FDA and Congress Move to Stop Unproven Stem Cell Interventions
Agency’s jurisdiction over regenerative therapies upheld in landmark court ruling The Food and Drug Administration and members of Congress have taken important steps in recent months to protect consumers from unproven and risky stem cell products offered by hundreds of clinics nationwide. However, the agency needs to take broader action to deter businesses from selling